Literature DB >> 2293412

In vitro measurement of phosphorylated zidovudine in peripheral blood leucocytes.

B N Stretcher1, A J Pesce, J R Wermeling, P E Hurtubise.   

Abstract

A method has been developed to measure the concentration of total phosphorylated zidovudine (ZDV) inside peripheral blood leucocytes (PBLs) using a modified commercial radioimmunoassay (RIA) specific for ZDV. ZDV 5'-monophosphate was readily synthesized and used as a procedural control for RIA modification. PBLs were isolated from healthy volunteers and incubated with ZDV for 24 h to allow metabolic phosphorylation. Viable cells were counted, washed, and extracted overnight with 60% methanol. After evaporation, the extract was reconstituted in Tris buffer, pH 9.5. Because of minimal RIA antibody cross reactivity with phosphorylated ZDV, samples were split into two fractions, one of which was treated with alkaline phosphatase (AP) to liberate phosphate groups. Each fraction was then assayed for ZDV. Concentrations of phosphorylated ZDV were determined by subtracting the concentration of the non-AP-treated fraction from that of the treated fraction. Recovery of phosphorylated ZDV from cell extracts was approximately 90%, and reproducibility was acceptable (coefficients of variation less than 15% for concentrations greater than or equal to 0.25 ng/ml). Intracellular concentrations (0.1-1.4 pmoles/10(6) cells) followed a nonlinear dose-response relationship over the range 0-50 microM extracellular ZDV, with concentration-dependent saturation. These results demonstrate the feasibility of determining concentrations of phosphorylated ZDV in HIV-infected patients, a potentially key step in establishing a therapeutic range and optimal dosing regimen for these patients.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2293412     DOI: 10.1097/00007691-199009000-00013

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  11 in total

1.  Pharmacokinetics of zidovudine phosphorylation in human immunodeficiency virus-positive thai patients and healthy volunteers.

Authors:  Y Wattanagoon; K Na Bangchang; P G Hoggard; S H Khoo; S E Gibbons; D Phiboonbhanakit; J Karbwang; D J Back
Journal:  Antimicrob Agents Chemother       Date:  2000-07       Impact factor: 5.191

2.  Determination of zidovudine triphosphate intracellular concentrations in peripheral blood mononuclear cells from human immunodeficiency virus-infected individuals by tandem mass spectrometry.

Authors:  E Font; O Rosario; J Santana; H García; J P Sommadossi; J F Rodriguez
Journal:  Antimicrob Agents Chemother       Date:  1999-12       Impact factor: 5.191

Review 3.  Pharmacokinetic optimisation of antiretroviral therapy in patients with HIV infection.

Authors:  B N Stretcher
Journal:  Clin Pharmacokinet       Date:  1995-07       Impact factor: 6.447

Review 4.  Pharmacokinetic individualisation of zidovudine therapy. Current state of pharmacokinetic-pharmacodynamic relationships.

Authors:  R M Hoetelmans; D M Burger; P L Meenhorst; J H Beijnen
Journal:  Clin Pharmacokinet       Date:  1996-04       Impact factor: 6.447

Review 5.  Zidovudine. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

Authors:  Michelle I Wilde; Heather D Langtry
Journal:  Drugs       Date:  1993-09       Impact factor: 9.546

6.  Evidence of alkaline phosphatase interference in a zidovudine radioimmunoassay.

Authors:  A M O'Donnell; D J Letting; M F DeRemer; G D Morse
Journal:  Antimicrob Agents Chemother       Date:  1994-12       Impact factor: 5.191

7.  Pharmacokinetics of zidovudine phosphorylation in peripheral blood mononuclear cells from patients infected with human immunodeficiency virus.

Authors:  B N Stretcher; A J Pesce; P T Frame; D S Stein
Journal:  Antimicrob Agents Chemother       Date:  1994-07       Impact factor: 5.191

Review 8.  Comparative pharmacokinetics of antiviral nucleoside analogues.

Authors:  G D Morse; M J Shelton; A M O'Donnell
Journal:  Clin Pharmacokinet       Date:  1993-02       Impact factor: 6.447

9.  Comparison of rates of intracellular metabolism of zidovudine in human and primate peripheral blood mononuclear cells.

Authors:  M Qian; G Chandrasena; R J Ho; J D Unadkat
Journal:  Antimicrob Agents Chemother       Date:  1994-10       Impact factor: 5.191

10.  Effects of dideoxyinosine and dideoxycytidine on the intracellular phosphorylation of zidovudine in human mononuclear cells.

Authors:  G J Veal; M J Wild; M G Barry; D J Back
Journal:  Br J Clin Pharmacol       Date:  1994-10       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.